China Conjunctivitis Therapeutics Market Analysis

China Conjunctivitis Therapeutics Market Analysis Executive Summary

The China Conjunctivitis Therapeutics Market is at around $330 Mn in 2022 and is projected to reach $562 Mn in 2030, exhibiting a CAGR of 6.9% during the forecast period.

Conjunctivitis, commonly known as pink eye, is the inflammation of the conjunctiva, a transparent membrane covering both the eyelid and the surface of the eye. It can be triggered by various factors, including viral or bacterial infections, allergic reactions, irritants, and exposure to chemicals. Symptoms of conjunctivitis encompass redness, irritation, excessive tearing, and, in some cases, a gritty sensation or the presence of mucous discharge. The diagnosis typically involves a comprehensive eye examination, and the appropriate treatment varies based on the root cause. Allergic conjunctivitis may be addressed through nonsteroidal anti-inflammatory medications, antihistamines, or topical steroid eye drops. Conversely, infectious conjunctivitis, particularly the bacterial form, is commonly treated with antibiotic eye drops or ointments. Companies like Pfizer, Sanofi, Alcon, and Allergan are among the manufacturers producing these treatment options.

China is experiencing an increasing burden of conjunctivitis which affects more than 7% of the total population in the country. The factors contributing to the growth of this market include the surge in the prevalence of conjunctivitis, the evolving treatment landscape in the industry, and supportive government initiatives. However, conditions such as lack of human resources, health system challenges, saturation of the market, and others impede the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Rising burden of conjunctivitis: China faces elevated levels of air pollution, leading to eye irritation and contributing to the prevalence of conjunctivitis which affects 7% of the Chinese population. The trends of urbanization and evolving lifestyles, marked by increased exposure to allergens, expose individuals to a greater number of potential triggers for conjunctivitis. Additionally, with an aging population, the likelihood of age-related eye diseases, including conjunctivitis, is on the rise.

Evolving treatment landscape: Pharmaceutical firms are placing a greater emphasis on developing enhanced and novel treatments for conjunctivitis, encompassing targeted therapies, combination drugs, and formulations with prolonged effectiveness. The increasing approval of over-the-counter (OTC) remedies for mild cases of conjunctivitis is broadening market availability and providing added convenience for patients. The shift towards personalized medicine is fostering the advancement of targeted therapies tailored to the specific cause and severity of conjunctivitis.

Supportive government initiatives: The Chinese government has initiated programs aimed at enhancing awareness of eye health and increasing the accessibility of eye care services, indirectly encouraging the utilization of treatments for conjunctivitis. The “Healthy China 2030” plan aims to promote eye health through initiatives like the National Eye Health Plan allowing early diagnosis and prompt treatment thus expanding the market.

Market Restraints

Health system challenges: Unequal distribution of ophthalmologists, especially in rural areas, results in restricted access to specialized diagnosis and treatment. Patients often depend on primary care physicians, increasing the risk of misdiagnosis and improper medication, which can negatively affect treatment effectiveness and hinder market growth.

Market saturation: For specific conjunctivitis treatments, especially for mild cases, the market is nearing saturation, posing difficulties for new entrants to establish a substantial market share. Companies may need to explore opportunities in niche markets, consider combination therapies, or adopt innovative treatment approaches to distinguish themselves.

Strong presence of generics: The widespread availability of generic drugs in China creates a challenge for the pricing and profitability of branded therapeutics, potentially constraining the growth of innovative products in the market. To navigate this, companies may have to emphasize differentiation through distinctive formulations, targeted marketing strategies, and the provision of value-added services.

Workforce shortage: China is experiencing a scarcity of adequately trained ophthalmologists, especially in rural regions. This deficit restricts the availability of specialized care for individuals with conjunctivitis and impedes timely diagnosis and treatment.

Notable Updates

May 2023, Ocumension Therapeutics, Nicox's partner in China, has attained priority review status for the New Drug Application (NDA) of Zerviate (cetirizine ophthalmic solution), 0.24%, granted by China's National Medical Products Administration (NMPA). Zerviate, the sole eye drop formulation of the antihistamine cetirizine, is designed to address ocular itching linked to allergic conjunctivitis.

July 2020, IACTA Pharmaceuticals, Inc. and Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited, a prominent pharmaceutical company based in Hong Kong, have officially entered into a definitive license agreement. This agreement pertains to the licensing of two products developed by the Company, namely IC 265 designed for addressing dry eye and IC 270 intended for treating allergic conjunctivitis. The exclusivity of this license is specifically for ophthalmic indications within the region of China.

Healthcare Policies and Regulatory Landscape

The main regulatory body overseeing drugs and pharmaceuticals in China is the China National Medical Products Administration (NMPA). Formerly known as the China Food and Drug Administration (CFDA), the NMPA is responsible for the regulation and supervision of pharmaceuticals, medical devices, and food safety in the country. It plays a crucial role in ensuring the safety, efficacy, and quality of drugs available in the Chinese market. The NMPA establishes and enforces regulations, evaluates product registrations, and conducts inspections to maintain compliance with national standards.

To obtain licensure for drugs and pharmaceuticals in China, companies typically need to undergo a rigorous regulatory approval process. The NMPA reviews the submissions to ensure that the products meet the required safety and efficacy standards. Once approved, the products receive a license to be marketed and sold in China.

For new entrants to the pharmaceutical market, navigating this regulatory environment can be challenging due to the stringent requirements and the need for a thorough understanding of Chinese regulatory procedures. New companies invest significant time and resources to meet the regulatory criteria and gain approval for their products in compliance with Chinese regulations.

Competitive Landscape

Key Players

• Novartis
• Alcon
• Santen Pharmaceutical
• Shanghai Fosun
• Hengrui Medicine
• Hao Pharma
• Bausch & Lomb
• NicOx SA
• Allergan
• Alembic Pharmaceuticals